SMA Press
ISIS PHARMACEUTICALS REPORTS INTERIM RESULTS FROM ISIS-SMNRX MULTIPLE DOSE STUDY IN CHILDREN WITH SPINAL MUSCULAR ATROPHY
ISIS PHARMACEUTICALS REPORTS INTERIM RESULTS FROM ISIS-SMNRX MULTIPLE DOSE STUDY IN CHILDREN WITH SPINAL MUSCULAR ATROPHY Average increase of 3.7 points observed in muscle function score in SMA children treated with 9 mg of ISIS-SMNRx ISIS- SMNRx increases SMN protein in children with SMA On track to initiate Phase 3 study in children with SMA…
Read MoreJoint Program in Spinal Muscular Atrophy Enters First Stage of Clinical Development
South Plainfield, NJ, January 22, 2014 – PTC Therapeutics, Inc. (NASDAQ: PTCT), the SMA Foundation, and Roche (SIX: RO, ROG; OTCQX: RHHBY), announced today that their joint research program in Spinal Muscular Atrophy (SMA) has entered the first stage of clinical development aiming to assess safety and tolerability of an oral compound in healthy volunteers.…
Read MoreUnited States Senate Unanimously Passes the National Pediatric Research Network Act (NPRNA) Supporting SMA Research
United States Senate Unanimously Passes the National Pediatric Research Network Act (NPRNA) Supporting SMA Research Headed to the President’s desk today for signature, the legislation establishes a network of research consortia to focus on pediatric rare diseases, specifically including SMA. Friday, November 15, 2013 Unanimously passed by the U.S. Senate on Thursday night,…
Read MoreIsis Reports Follow-Up Data From ISIS-SMN Rx Phase 1 Study In Children With Spinal Muscular Atrophy
Isis Reports Follow-Up Data From ISIS-SMN Rx Phase 1 Study In Children With Spinal Muscular Atrophy Improvements in muscle function continue to be observed up to fourteen months after a single dose CARLSBAD, Calif., Sept. 19, 2013 /PRNewswire/ — Isis Pharmaceuticals, Inc.(NASDAQ: ISIS) announced today that follow-up preliminary data from a single dose, open-label Phase…
Read MoreISIS Pharmaceuticals Initiates a Clinical Study of ISIS-SMNRx in Infants with Spinal Muscular Atrophy
ISIS Pharmaceuticals Initiates a Clinical Study of ISIS-SMNRx in Infants with Spinal Muscular Atrophy Isis to Earn $3.5 Million Milestone Payment CARLSBAD, Calif., April 23, 2013 – Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced the initiation of a Phase 2 study of ISIS-SMNRx in infants with spinal muscular atrophy (SMA). SMA is a severe and…
Read MoreData from Phase 1 Study of ISIS-SMNRx in Children with SMA Presented at American Academy of Neurology Meeting
Isis hosted an investor event and live webcast at 7:30 am PT on Thursday, March 21 in San Diego CARLSBAD, Calif., March 20, 2013 – Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced that data from the Phase 1 study of ISIS-SMNRx in children with spinal muscular atrophy (SMA) were presented today at the 65th American Academy…
Read More